Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Erytech Pharma SA - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Erytech Pharma SA - Product Pipeline Review - 2015', provides an overview of the Erytech Pharma SA's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Erytech Pharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Erytech Pharma SA including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Erytech Pharma SA's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Erytech Pharma SA's pipeline products Reasons to buy - Evaluate Erytech Pharma SA's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Erytech Pharma SA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Erytech Pharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Erytech Pharma SA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Erytech Pharma SA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Erytech Pharma SA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Erytech Pharma SA Snapshot 5 Erytech Pharma SA Overview 5 Key Information 5 Key Facts 5 Erytech Pharma SA - Research and Development Overview 6 Key Therapeutic Areas 6 Erytech Pharma SA - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Erytech Pharma SA - Pipeline Products Glance 10 Erytech Pharma SA - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 Erytech Pharma SA - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Erytech Pharma SA - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Erytech Pharma SA - Drug Profiles 14 asparaginase 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Cell therapy for Phenylketonuria 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Enhoxy 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ERY-MET 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ERY-VAX 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ERYTOL 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Erytech Pharma SA - Pipeline Analysis 21 Erytech Pharma SA - Pipeline Products by Target 21 Erytech Pharma SA - Pipeline Products by Route of Administration 22 Erytech Pharma SA - Pipeline Products by Molecule Type 23 Erytech Pharma SA - Pipeline Products by Mechanism of Action 24 Erytech Pharma SA - Recent Pipeline Updates 25 Erytech Pharma SA - Dormant Projects 30 Erytech Pharma SA - Locations And Subsidiaries 31 Head Office 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Erytech Pharma SA, Key Information 5 Erytech Pharma SA, Key Facts 5 Erytech Pharma SA - Pipeline by Indication, 2015 7 Erytech Pharma SA - Pipeline by Stage of Development, 2015 8 Erytech Pharma SA - Monotherapy Products in Pipeline, 2015 9 Erytech Pharma SA - Phase III, 2015 10 Erytech Pharma SA - Phase II, 2015 11 Erytech Pharma SA - Phase I, 2015 12 Erytech Pharma SA - Preclinical, 2015 13 Erytech Pharma SA - Pipeline by Target, 2015 21 Erytech Pharma SA - Pipeline by Route of Administration, 2015 22 Erytech Pharma SA - Pipeline by Molecule Type, 2015 23 Erytech Pharma SA - Pipeline Products by Mechanism of Action, 2015 24 Erytech Pharma SA - Recent Pipeline Updates, 2015 25 Erytech Pharma SA - Dormant Developmental Projects,2015 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.